Bioasis Technologies (BIOAF) Stock Price, News & Analysis

Company Overview

Bioasis Technologies Inc. is a clinical-stage biotechnology company based in Vancouver, Canada, focused on advancing novel delivery technologies to transport therapeutic molecules across the blood–brain barrier (BBB). The company’s proprietary Blood–Brain Barrier Transport (BBBT) platform is designed to enable targeted delivery of peptides, proteins and enzyme replacement therapies to the central nervous system, addressing a critical challenge in treating neurological and rare lysosomal storage disorders.

Bioasis’s pipeline leverages its BBBT platform to develop preclinical candidates for a range of central nervous system indications. The technology has been evaluated in multiple animal models and is engineered to improve the uptake and distribution of therapeutic payloads in brain tissue. By partnering or licensing its platform to larger pharmaceutical and biotechnology firms, Bioasis aims to accelerate the development of next-generation treatments for conditions such as Alzheimer’s disease, Parkinson’s disease and various pediatric metabolic disorders.

Founded in Vancouver, Bioasis is publicly traded on the OTC Markets under the ticker symbol BIOAF. The company maintains its research and development operations in Canada and collaborates with academic institutions and industry partners to validate and expand its BBBT applications. With a focus on overcoming one of the most significant hurdles in neurotherapeutics, Bioasis strives to create new opportunities for effective brain-targeted medicines.

Key Stats

• Today's Range: $0.0006 to $0.0006
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0130
• Volume: 2,300 shs
• Average Volume: 115 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BIOAF Stock Analysis - Frequently Asked Questions

How have BIOAF shares performed this year?

Bioasis Technologies' stock was trading at $0.0001 at the start of the year. Since then, BIOAF shares have increased by 500.0% and is now trading at $0.0006.

How were Bioasis Technologies' earnings last quarter?

Bioasis Technologies Inc. (OTCMKTS:BIOAF) released its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.01) EPS for the quarter, meeting analysts' consensus estimates of ($0.01).

How do I buy shares of Bioasis Technologies?

Shares of BIOAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 10/27/2021
• Today: 9/13/2025
• Fiscal Year End: 2/28/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BIOAF
• CIK: N/A
• Web: www.bioasis.us
• Phone: (203) 533-7082
• Fax: N/A
• Employees: N/A
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.55